Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and sof
- PDF / 634,840 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 15 Downloads / 146 Views
PHASE II STUDIES
Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma Zhichao Tian 1 & Huimin Liu 2 & Fan Zhang 1 & Liangyu Li 3 & Xinhui Du 1 & Chao Li 1 & Jinpo Yang 4 & Jiaqiang Wang 1 Received: 4 December 2019 / Accepted: 12 February 2020 # The Author(s) 2020
Summary Background Previous studies have demonstrated the efficacy of apatinib and anlotinib for the treatment of sarcomas. However, more clinical data and evidence are needed to support clinical treatment selection and study design. Here, we evaluated the effectiveness and safety of these two drugs for the treatment of sarcomas. Methods We retrospectively reviewed the data of 110 patients with advanced osteosarcoma (n = 32) or soft tissue sarcoma (STS, n = 78) who received oral apatinib or anlotinib therapy during May 2016–February 2019 at two centers. Patients were divided into the apatinib and anlotinib groups. Results Among osteosarcoma patients, the objective response rates (ORRs) for the apatinib and anlotinib groups were 15.79% (3/19) and 7.69% (1/13), respectively. The disease control rates (DCRs) were 63.16% (12/19) and 30.77% (4/13), and the median progression-free survival (m-PFS) was 4.67 ± 3.01 and 2.67 ± 1.60 months, respectively. Among STS patients, ORRs for the apatinib and anlotinib groups were 12.24% (6/49) and 13.79% (4/29), respectively. The DCRs were 59.18% (29/49) and 55.17% (16/29), and m-PFS was 7.82 ± 6.90 and 6.03 ± 4.50 months, respectively. Regarding adverse events (AEs), apatinib was associated with a higher incidence of hair hypopigmentation and pneumothorax, while anlotinib was associated with a higher incidence of pharyngalgia or hoarseness. Conclusion Both apatinib and anlotinib were effective for the treatment of sarcomas. However, the effectiveness of the two drugs and associated AEs varied based on the histological type of sarcoma. These differences may be due to their different sensitivities to targets such as RET, warranting further study. Keywords Tyrosine kinase inhibitor . Osteosarcoma . Soft tissue sarcoma . Adverse events . Pneumothorax
Introduction Sarcomas are malignancies of mesenchymal origin, of which more than 70 histological subtypes have been identified [1–3].
* Jiaqiang Wang [email protected] 1
Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China
2
Department of Medical Oncology, The Affiliated People’s Hospital of Zhengzhou University, Zhengzhou 450003, Henan Province, China
3
Department of Orthopedics, the People’s Hospital of Jiyuan, Jiyuan 459000, Henan Province, China
4
Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China
Sarcomas are relatively rare, with an annual incidence of fewer than 5 cases per 100,000 people, and these malignancies account for 1–2% of all adult cancers [1, 3]. Despite the rarity
Data Loading...
